Advance in p53 gene treatment of primary liver cancer
10.3760/cma.j.cn113884-20230406-00102
- VernacularTitle:p53基因在原发性肝癌中的作用的研究进展
- Author:
Zhaowei DING
1
;
Yongqing YE
;
Ping WANG
Author Information
1. 广州医科大学附属第一医院肝胆外科，广州 510120
- Keywords:
Genes, p53;
Liver cancer;
Cancer therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2023;29(11):870-874
- CountryChina
- Language:Chinese
-
Abstract:
Liver cancer is one of the most common and fatal malignancies worldwide, with high mortality and morbidity. As an important tumor suppressor gene, p53 gene plays a key role in cell cycle regulation, cell growth and apoptosis of tumor cells. P53 gene mutations are closely related to the occurrence of liver cancer. At present, the treatment of liver cancer includes surgery, local treatment and systemic treatment. However, since most liver cancer patients are in advanced stages at the time of diagnosis, non-surgical treatment has become the best choice for the treatment of patients with intermediate and advanced liver cancer. But patients still have problems such as short survival and easy drug resistance. Therefore, the development of new treatment options is essential to improve the treatment outcomes of liver cancer patients. P53-related gene therapy products have great potential as drugs for the treatment of liver cancer. This article will briefly review the relationship between p53 gene and primary liver cancer, and explore its role in diagnosis and treatment, in order to provide a new direction for future clinical treatment.
